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Abstract 
Chemopreventives are natural or synthetic compounds that are used to stop or reverse the 
processes of carcinogenesis or tumorigenesis. Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene) is a 
stilbenoid and natural phenol that is found in fruits such as grapes. In addition to antioxidant and 
anti-inflammatory properties, resveratrol can inhibit D-type cyclins and cyclin-dependent kinase 
CDK4 expression. This can also lead to inducing tumor suppressors p53 and Cdk inhibitor p21. 
The p53 protein is encoded by the TP53 gene and responds to cellular stresses by regulating 
target genes that induce cell cycle arrest, apoptosis, and DNA repair among other functions. 3-
nitro-2-styryl amide derivatives contain the stilbene structure similar to resveratrol and due to 
this similarity will be effective chemopreventives. We have synthesized five 3-nitrostyrylamides 
to be tested for their chemopreventive efficacy. These compounds were synthesized using a base 
catalyzed condensation reaction that utilized substituted benzaldehydes and methyl 2-methyl 3 
nitrobenzoate to form 3-nitro-2-styrl benzoic acids to give percent yields of 35.1-90.2%. The 
conversion of the 3-nitro-2-styryl benzoic acids to acid chlorides was completed using an N, N-
dimethylformamide catalyzed reaction with thionyl chloride. The acid chlorides were converted 
to amides using N-butylamine and sodium hydroxide to give percent yields of 15.9-87.7%. The 
synthesized amide compounds were characterized using 
1
H NMR, 
13
C NMR, FT-IR, and HPLC. 
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CHAPTER 1 
Introduction 
According to the American Cancer Society, a total of 1,660,290 new cancer cases and 
580,350 deaths from cancer were projected to occur in the United States in 2013, for all invasive 
cancer sites. One in every four males in the US will die from cancer, while one in every five 
females will die from the disease (American Cancer Society, 2013). Given the negative impact of 
cancer on health, there is a need to find a method to prevent the disease. One approach to 
preventing cancer is to prevent the onset of cancer which is called carcinogenesis. 
Carcinogenesis is the mechanism by which normal cells are transformed into cancerous cells. 
These cells are identified by uncontrolled cell growth. Chemoprevention is the use of natural and 
synthetic compounds to inhibit carcinogenesis(Tsao, Kim, & Hong, 2004). 
1.1 Carcinogenesis and Cancer Chemoprevention 
 Cancer pathology studies led to the discovery that carcinogenesis is a multistep 
mechanism. Somatic mutations in a single cell accumulate to cause phenotypic change from 
hyperplastic (causing an abnormal increase in the number of cells) to dysplastic (causing 
abnormal growth and development of cells). Dysplastic phenotypes can eventually become fully 
malignant. When cells become malignant, there are two classes of genes, proto-oncogenes and 
tumor suppressor genes that play a role in carcinogenesis(Tsao et al., 2004). Tumor suppressor 
genes and proto-oncogenes are essential in transcription regulation, cell cycle control, and signal 
transduction. These three activities of the genes contribute to the three phases of carcinogenesis 
(initiation, promotion and progression)(Tsao et al., 2004).  
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Figure 1: Three phases of carcinogenesis(Kang, Shin, Lee, & Lee, 2011) 
The schematic in figure 1 shows this three phase process. Initiation is a short and irreversible 
process normally requiring many years before full malignancy is reached. The preneoplastic cells 
shown before progression are simply those preceding the development of a tumor. It is important 
to note that the promotion phase, while long-term, is reversible(Kang et al., 2011). This reversal 
is precisely the aim of chemoprevention. In figure 1, the method of chemoprevention shown is 
the use of polyphenols. Polyphenols are natural and synthetic molecules containing multiple 
phenol groups(Kuroda & Hara, 1999). They possess unique chemical and physical properties that 
make them of interest in chemoprevention. The compounds proposed in this study are designed 
to maximize these properties. 
It is also essential to note the specific genes involved in carcinogenesis. One of these 
specific genes is KRAS(Horvath et al., 2004). This oncogene is responsible for providing 
instructions to make the protein K-Ras that regulates cell division(Juan, Wenzel, Daniel, & 
Planas, 2008). The Ras family of oncogenes also includes HRAS and NRAS which are 
responsible for cell proliferation and cell apoptosis (death) respectively(Juan et al., 2008). 
Mutations in the KRAS gene ultimately cause cancer by allowing the K-Ras protein to become 
overactive which accounts for the uncontrolled growth of cancerous cells. One specific pathway 
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to chemoprevention is to provide a detour to the multistep mechanism involving K-Ras. The 
nitrostyrenyl amides synthesized in this study will accomplish this detour by inducing the p53 
protein that can in turn induce cell cycle arrest and apoptosis to bypass the K-Ras pathway ((Lee, 
Zhang, & Sanderson, 2008).  
 
Figure 2: Multistep Carcinogenesis Model(Tsao et al., 2004) 
The diagram shown in figure 3, shows a biological path to preventing cancer 
development using apoptotic agents. The compounds proposed in this study will be studied for 
their ability to initiate apoptosis. The diagram also shows the pathway by which these 
compounds can serve as antiangiogenic agents which prevent the growth of new blood vessels 
caused by carcinogens. The inhibition of the growth of these blood vessels is essential in 
chemoprevention. 
6 
 
 
 
Figure 3: Biological Approaches to Preventing Cancer Development(Tsao et al., 2004) 
1.2 Types of Chemopreventives 
 Cancer chemopreventives are natural or synthetic compounds with the ability to prevent 
the process of carcinogenesis. Dietary components such as ascorbic acid, β-carotene, folic acid 
and vitamin E are examples of compounds that have been studied in cancer chemoprevention 
(Sporn & Lippman, 2003). There exists the need for a wide range of potent agents in cancer 
chemoprevention. Chemopreventives have to be potent while maintaining low cytotoxicity. The 
compounds synthesized in this study seek to add to the knowledge base of what structural 
functionalities are ideal for chemopreventive drug design. 
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1.2.1 Blocking Agents and Suppressing Agents. Chemopreventives can be described by 
two major categories; blocking agents or suppressing agents. Blocking agents prevent the 
initiation of carcinogenesis, while suppressing agents prevent further progression of cancer 
(Sporn & Lippman, 2003).  
 1.2.1.1 Blocking Agents.  
 1.2.1.1.1 Hormonal Antagonists: Some chemopreventives mode of action involves 
interaction with hormone receptors. One of the well-known hormonal antagonists is tamoxifen. 
Tamoxifen is a non-steroidal triphenylethylene derivative that is believed to bind to the estrogen 
receptor to prevent mammary cell proliferation (Sporn & Lippman, 2003).  
 
C2H5
(H3C)2N(H2C)2O
 
Figure 4: Structure of Tamoxifen 
Another possibility is that, similar to fetal fibroblast cells,  tamoxifen could induce production of 
the transforming growth factor-β, which is a negative autocrine regulator. In breast cancer 
patients, tamoxifen has also been shown to lower an insulin-like growth factor which enhances 
their growth. A disadvantage to using tamoxifen is that it has estrogenic effects on the epithelium 
of the uterus that increase the risk of developing uterine cancer
 
(Sporn & Lippman, 2003). 
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Raloxifene (Figure 4) is a drug said to have a similar mode of action to tamoxifen, while also 
inhibiting the proliferation of uterine epithelia. 
N
O
O
S
OH
HO
 
Figure 5: Structure of Raloxifene 
The pharmacological activity of raloxifen is unique in that its estrogenic effect also has a positive 
effect on bone and serum lipids
 
(Sporn & Lippman, 2003). For this reason, it is commonly used 
to treat osteoporosis and is being evaluated as a chemopreventive agent. 
 1.2.1.1.2 Nonsteroidal Anti-inflammatory Drugs: Nonsteroidal anti-inflammatory drugs 
(NSAIDs) include aspirin, ibuprofen, sulindac and piroxicam. These drugs have been studied in 
chemoprevention due to their ability to block prostaglandin synthesis by inhibiting 
cyclooxygenase (Sporn & Lippman, 2003). Since they are commonly used, researchers have 
been able to utilize already established dosage data in ongoing chemoprevention studies. In 
9 
 
 
animal studies NSAIDs are believed to act as blocking agents and may be particularly effective 
for prevention of carcinogenesis in the colon.  
N
N
F
F
F
S
H2N
O O
H3C  
Figure 6: Structure of celecoxib 
Within the NSAID category, cyclooxygenase-2 (COX-2) inhibitors are of increased interest. The 
COX-2 inhibitor, celecoxib is believed to be an effective chemopreventive for lung cancer (Mao 
et al., 2011). 
 1.2.1.2 Suppressing Agents 
 1.2.1.2.1 Retinoids: Retinoids are natural and synthetic and natural analogues of retinol 
(Figure 1), Vitamin A. This class of molecules has been shown to regulate the growth of 
epithelial cells. They interact with receptors that are active in the regulation of transcription of 
the genes that control cell differentiation and proliferation of epithelia. Retinoid deficiency leads 
to failure of stem cells to mature correctly and cell proliferation causing the formation of 
premalignant tissue (Sporn & Lippman, 2003). Animal studies of retinoids have shown efficacy 
in epithelial sites including breasts, pancreas, liver, prostate and the lungs. These agents have 
also been studied in combination with the preventative, tamoxifen. 
10 
 
 
OH
CH3 CH3
CH3
H3C CH3
 
Figure 7: Structure of Retinol 
 1.2.1.2.2 Deltanoids: Another group in the steroid receptor family, like retinoids, is 
deltanoids. These include vitamin D and synthetic molecules of structural similarity. 
CH2
H OH
H
CH3
CH3
CH3
H3C
 
Figure 8: Structure of Vitamin D 
The mode of actions for this class of molecules is the controlled expression of genes that induce 
cell differentiation. Newer deltanoid analogues are sought to reduce the calcemic nature of these 
drugs. In animal studies, they have been shown to have preventative affects for breast cancer
 
(Sporn & Lippman, 2003). 
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CHAPTER 2 
Literature Review 
2.1 Stilbene  
 Stilbene based molecules are widely found in nature and are of particular interest in 
chemoprevention due to their biological function. Because stilbenes have been shown to prevent 
the growth of cancerous cells of the colon, prostate, breast, pancreas, ovaries, skin, head and 
neck(Rimando & Suh, 2008), we envisage that they would make effective chemopreventives. 
 2.1.1 Synthesis of Trans Stilbene: A common approach to the synthesis of trans stilbene 
is the Wittig reaction. The Wittig reaction easily converts a ketone or aldehyde to an alkene 
using a phosphorus ylide without producing side products that must be removed. The phosphorus 
ylide is generated from a phosphonium salt such as benzyltriphenyl-phosphonium chloride 
shown below. 
 
PPh3Cl
1. NaOH
2. PhCHO
+
trans-stilbene
cis-stilbene
benyltriphenyl-phosphonium chloride
 
Figure 9: Wittig Reaction Synthesis of Stilbene 
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The reaction, Figure 9, yields both the cis and trans products. The mechanism is the cis-stilbene 
can then be converted to the favored trans-stilbene using crystalline iodine(Chang, Na, Shin, 
Choi, & Jeong, 2002). 
 2.1.2 Stilbenoids: Hydroxlated derivatives of stilbene, stilbenoids, are byproducts of 
heartwood formation in trees (Likhtenshtein, 2010). Growth inhibition of cancer cells is caused 
by cell cycle arrest from proteins p21, p27 and p53. This cell cycle arrest can also occur through 
a protein dependent mechanism called Fas-associated Death Domain (FADD), which involves 
this protein connecting the Fas-receptor (apoptosis antigen-1) to form a signaling complex 
necessary for apoptosis  (Rimando & Suh, 2008). A major benefit of stilbenoids is their ability to 
induce apoptosis in a highly selective manner through the activation of Fas. Stilbenoids can 
target a wide variety of cancerous biological targets(Lion, Matthews, Stevens, & Westwell, 
2005). 
2.2 Resveratrol 
 Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene) is a stilbenoid and natural phenol that is 
found in fruits such as grapes (Horvath et al., 2004; Lion et al., 2005). It is an important structure 
to use as a building block for new chemopreventives due to its proven effectiveness in biological 
function (Figure 10) (Juan, Wenzel, Daniel, & Planas, 2008). Resveratrol, as a phytoalexin, 
exhibits prominent effects on the cellular processes responsible for cancer initiation, promotion 
and progression(Lee et al., 2008). The polyphenol structure attributes to antioxidant behavior. As 
an antioxidant, resveratrol can reduce the formation of reactive oxygen species in blood platelet 
to effect oxidant-induced apoptosis (programmed cell death). Anti-inflammatory behavior of 
resveratrol is due to the inhibition of prostaglandin production. In addition to antioxidant and 
anti-inflammatory properties, resveratrol can inhibit D-type cyclins and cyclin-dependent kinase 
13 
 
 
CDK4 expression (Lee, Zhang, & Sanderson, 2008; Liang, Tajmir-Riahi, & Subirade, 2007). 
This can also lead to inducing tumor suppressors p53 and Cdk inhibitor p21. The p53 protein is 
encoded by the TP53 gene and responds to cellular stresses by regulating target genes that induce 
cell cycle arrest, apoptosis, and DNA repair among other functions (Juan, Wenzel, Daniel, & 
Planas, 2008). Inducing p53 is a goal of the compounds to be synthesized in this study. 
OH
HO
OH  
Figure 10: Structure of Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene) 
In order for chemopreventives to be effective and useful, they must exhibit low cytotoxicity. This 
means that they have very minimalized effects on normal, healthy cells. Resveratrol has 
exhibited selective cytotoxicity toward malignant cells with minimal cytotoxicity toward normal 
cells in some studies. However, other studies have shown that depending upon concentration, 
resveratrol can affect the proliferation of nonmalignant cells(Liang et al., 2007). This study seeks 
to produce compounds that retain resveratrol’s chemopreventive properties through structural 
similarity, while minimizing cytotoxic effects on normal cells. The 3-nitro-2-styrenyl benzoic 
acids and their amide derivatives will utilize functional groups that are naturally occurring in the 
body to minimize cytotoxic effects leaving nonmalignant cell proliferation unaffected.  
 2.2.1 Synthesis of Resveratrol: In plants, the natural biosynthesis of resveratrol is 
achieved by the enzyme resveratrol synthase. However, the compound can also be achieved 
synthetically utilizing the Wittig reaction. 
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Figure 11: Synthesis of trans-resveratrol via Wittig reaction 
The Wittig reaction occurs between the phosphonium salt of 4-methoxybenzyl chloride and 3,5-
bis[tertbutyl(dimethylsilyl)oxy]benzaldehyde. The tertbutyldimethylsilyl groups are used to 
protect the hydroxyl groups on the benzaldehyde. Note that this reaction yields both the cis and 
trans isomers of resveratrol. The cis isomer can be separated using column chromatography 
before deprotection of the hydroxyl groups. The desilylation is achieved with 
tertbutylammonium fluoride to give the final product of (E)-resveratrol. This reaction can be 
carried out using any of these three organic solvents: ethanol, dichloromethane or hexanes. This 
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particular synthetic route has been patented by Thomas Christian Lines in the study of resveratrol 
as a treatment for mental disorders, including depression (Thomas Christian Lines, 2006). 
2.3 Significance of 3-nitro-2-styrenyl benzoic acids in Chemoprevention 
The compounds in this study are stilbene based derivatives with substituents aimed to 
enhance biological activity. 3-nitro-2-styrlbenzoic acid derivatives share the same structural 
motif as the known chemopreventive, resveratrol. Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene) 
is a stilbenoid and natural phenol that is found in fruits such as grapes(Horvath et al., 2004; Lion 
et al., 2005) As shown in figure 1, phenols are of particular interest in the development of 
chemopreventives. Due to the structural similarities between resveratrol and 3-nitro-2-
styrlbenzoic acid derivatives with substituents at the ortho and para positions, we believe that the 
3-nitro-2-styrl benzoic acid derivatives will be effective chemopreventives.  
R
ortho
meta
para  
Figure 12: Relative Positions on a Benzene Ring 
2.4 Amides 
In its neutral state, nitrogen can form three bonds with an additional lone pair of 
electrons. In amides one of the bonds is to a carbonyl group. The general structure of an amide is 
related to that of a carboxylic acid except that the hydroxyl group is replaced by a NR2 group. In 
the amide derivatives of nitrostyrenl benzoic acids, this change will reduce cytotoxicity and 
improve the potential for the synthesized compounds to act as chemopreventives. 
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Figure 13: General Structures of an Amide and a Carboxylic Acid 
 2.4.1 Solubility: The solubility of amides is greatly influenced by the dipoles created by 
the carbonyl bond and the nitrogen-carbon bond. These dipoles allow amides to be hydrogen 
bond acceptors. While this property gives amides better solubility than hydrocarbons and 
aromatic structures, they are not generally as soluble as carboxylic acids and amines. The low 
water solubility of amides poses a challenge to their use in drug discovery, however with the 
appropriate functional groups on the starting benzaldehydes, the compounds solubility can 
improve. 
 2.4.2 Reactivity: Amides are non-basic and non-acidic at physiological pH due to the 
electron withdrawing nature of the carbonyl attached to the nitrogen. They are also less likely to 
act as nucleophiles and to be attacked by nucleophiles during hydrolysis due to resonance. 
Amides that are sterically hindered with large substituents will exhibit slower hydrolysis. The 
fact that amides are less reactive than other groups at physiological pH can aid in lowering the 
compounds cytotoxicity and improve dosage tolerance. 
2.5 Amide Derivatives of 3-nitro-2-styrenyl benzoic acids 
 The amide derivatives of 3-nitro-2-styrenyl benzoic acids have a trans-stilbene structure 
with biologically active amide and nitro groups. Equally important is the electron withdrawing 
substituents on ring 2 located at the ortho and para positions (as labeled in figure 12). In our 
compounds, ring 1 has a nitro group at the ortho position and the amide at the meta position. The 
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substituents on ring 2 will be electron donating groups, such as methoxy and chloro groups. A 
push-pull mechanism will result from the placement of these groups in order to observe the 
reactivity of various structural motiffs. We believe that amide derivatives will maximize 
biological activity without increasing cytotoxicity.  
 2.5.1 Amide Derivatives Improve Biological Activity of Ibuprofen: The known anti-
inflammatory (NSAID) ibuprofen is widely used to treat the symptoms of pain, joint disease and 
rheumatoid arthritis. The mechanism of action is the inhibition of the COX enzyme and the 
production of prostaglandins. Ibuprofen and other NSAIDs exhibit negative side effects such as 
development of ulcers and dyspepsia(Mehta et al., 2010). These adverse effects are associated 
most of all with NSAIDs containing a free carboxylic acid group(Mehta et al., 2010). In a 2010 
study, it was shown that amide derivatives of ibuprofen (prodrugs) were able to retain the anti-
inflammatory activity while providing gastro protection, reducing the occurrence of adverse 
effects like ulcerogenicity.  
H3C
CH3
CH3
OH
O
 
Figure 14: Structure of Ibuprofen 
CH3
H
N
O
CH2OH
H3C
CH3
 
Figure 15: Structure of aminoprofen prodrug 
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2.5.1.1 Biological Activity Studies: Biological tests of the amide derivatives were done 
on Wistar rats in blind studies. The rats were treated for paw edema (painful swelling that can 
lead to infection) with a control, ibuprofen or the prodrug. All doses were administered at the 
molar equivalent basis of ibuprofen. The results showed a drastic decrease in ulcer index 
resulting from the aryl acetic moiety to the amides. The ulcer index for ibuprofen was measured 
at 4.0, while the amide prodrugs had ulcer indexes ranging from 0.5 to 1.0 (Mehta et al., 2010). 
All prodrugs tested showed comparable pharmacological activity to the parent drug with some 
even exhibiting improvement. 
 2.5.2 Sulindac Sulfide Amide Studies: In another carboxylic acid to amide drug 
conversion study, the drug Sulindac was studied. Sulindac is a NSAID prodrug derived from 
sulfinylindene(Piazza et al., 2009). Sulindac, like other NSAIDs has negative side effects 
stemming from the mechanism of COX enzyme and prostaglandin inhibition. While sulindac has 
shown promise as a chemopreventive, the toxicity to the gastrointestinal, renal and 
cardiovascular systems is too great for it to be effective(Piazza et al., 2009). Researchers were 
able to synthesize an amide derivative using an N, N-dimethylethyl amine substitution. This 
amide derivative did not exhibit inhibition to the COX enzyme, but was highly effective in 
inhibition of colon tumor cell growth(Piazza et al., 2009). In the HT-29 colon tumor cell line, the 
amide derivative was 40 times as potent against the cancer. 
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Figure 16: Structures of Sulindac Sulfide and Sulindac Sulfide Amide 
According to the study, the amide derivative also showed greater bioavailability than the 
sulindac sulfide. In addition to the colon tumor cell line studies, SSA was also studied on lung 
tumor cell lines (Gurpinar, 2013). 
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CHAPTER 3 
Methodology 
3.1 General Procedure  
 All chemical reagents used were purchased from Sigma-Aldrich, Fischer-Scientific and 
Acros Chemicals. The nitro Styrenyl benzoic acids were synthesized using a base catalyzed 
condensation reaction in which 1, 8-diazobicycloundec-7-ene was the base. Nitro Styrenyl 
benzoic acids were then converted to the respective amide derivatives using an N, N-
dimethylformamide catalyzed reaction of thionyl chloride producing an acid chloride that can 
then undergo substitution with a desired amine. All products were characterized using 
1
H NMR, 
13
C NMR and FT-IR. The NMR used was a Varian 300 MGHz utilizing VNMRJ software. The 
FT-IR was a Shimadzu IRPRESTIGE-21. HPLC analysis was done on a Varian ProStar. Melting 
point ranges for each compound were determined using a MEL TEMP apparatus and are 
recorded in degrees Celsius.  
3.2 Synthesis of Nitro Styrenyl Benzoic Acids (1a-8a) 
 The appropriately substituted benzaldehyde (11.5 mmol) was added to a round bottom 
flask equipped with a magnetic stir bar along with 1.50g of methyl-2-methyl-3-nitrobenzoate in 
10 mL of dried dimethylsulfoxide (DMSO). This reaction mixture was allowed to stir for 20 
hours at room temperature before being heated to 55°C for 4 hours, allowed to cool having 
sodium hydroxide (20mL, 1M) added to it. The reaction mixture is then washed with washes of 
ethyl acetate(2X 25 mL). The aqueous layer was made acidic with concentrated hydrochloric 
acid and extracted with ethyl acetate. The extracted reaction mixture was dried over magnesium 
sulfate and the solvent was removed by rotary evaporation. The resultant crude oil product was 
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recrystallized using dried methanol and water. Percent yields for these reactions ranged from 
35.1-90.2%. 
 3.2.1 2-[(E)-2-(2-chlorophenyl) ethenyl]-3-nitrobenzoic acid (1a): 1H NMR (301 
MHz, ACETONITRILE-  7.49 (s, 1 
H) 7.58 (t, J=1.00 Hz, 1 H) 7.74 (br. d, J=1.00 Hz, 1 H) 7.97 (s, 1 H) 8.08 (br. s., 1 H) 13C NMR 
(101 MHz, ACETONITRILE- -0.28 (s, 1 C) -0.07 (s, 1 C) 0.14 (s, 1 C) 0.35 (s, 1 C) 
0.49 (s, 1 C) 0.55 (s, 1 C) 0.76 (s, 1 C) 0.97 (s, 1 C) 11 .34 (s, 1    M  153-1 1  
 3.2.2 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a): 
1
H NMR 
(400 MHz, ACETONITRILE-d3)  ppm 6.62 (1 H, s), 7.66 (4 H, s), 8.04 (1 H, s), 8.21 (3 H, s) 
13
C NMR (101 MHz, ACETONITRILE-d3)  ppm 123.03 (s, 1 C) 125.83 (s, 1 C) 126.83 (s, 1 C) 
127.73 (s, 1 C) 127.93 (s, 1 C) 128.34 (s, 1 C) 128.74 (s, 1 C) 130.07 (s, 1 C) 131.29 (s, 1 C) 
132.50 (s, 1 C) 132.72 (s, 1 C) 133.20 (s, 1 C) 133.67 (s, 1 C) 135.31 (s, 1 C) 150.41 (s, 1 C) 
166.68 (s, 1      M  155-1    
 3.2.3 2-[(E)-2-(4-chlorophenyl)ethenyl]-3-nitrobenzoic acid (3a): 
1
H NMR (301 MHz, 
CHLOROFORM-d)  ppm 6.50 (br. d, J=1.00 Hz, 1 H) 7.36 (t, J=14.20 Hz, 5 H) 7.53 (br. d, 
J=1.00 Hz, 2 H) 7.98 (br. d, J=1.00 Hz, 1 H) 8.18 (br. d, J=1.00 Hz, 1 H) 
13
C NMR (101 MHz, 
ACETONITRILE-d3)  ppm 117.34 (s, 1 C) 121.64 (s, 1 C) 124.30 (s, 1 C) 126.59 (s, 1 C) 
127.90 (s, 1 C) 128.08 (s, 1 C) 128.42 (s, 1 C) 128.89 (s, 1 C) 131.22 (s, 1 C) 131.74 (s, 1 C) 
132.42 (s, 1 C) 133.51 (s, 1 C) 135.41 (s, 1    150.3  (s, 1    1  .   (s, 1    1  .   (s, 1     
M  150-1    
 3.2.4 2-[(E)-2-(4-bromophenyl) ethenyl]-3-nitrobenzoic acid (4a): 
1
H NMR (301 
MHz, CHLOROFORM-d)  ppm 6.47 (d, J=1.00 Hz, 1 H) 7.26 (s, 1 H) 7.33 (d, J=1.00 Hz, 2 H) 
7.48 (br. t, J=1.00, 1.00 Hz, 2 H) 7.55 (br. d, J=1.00 Hz, 1 H) 7.96 (br. d, J=1.00 Hz, 1 H) 8.17 
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(br. d, J=1.00 Hz, 1 H) 
13
C NMR (101 MHz, ACETONITRILE-d3)  ppm 117.33 (s, 1 C) 121.73 
(s, 1 C) 124.39 (s, 1 C) 126.69 (s, 1 C) 127.46 (s, 1 C) 128.35 (s, 1 C) 128.47 (s, 1 C) 131.   (s, 
1    131. 1 (s, 1    131.   (s, 1    13 .50 (s, 1    133.1  (s, 1    133.51 (s, 1    135.   (s, 1 
   1  . 1 (s, 1     M  14 -1    
 3.2.5 2-[(E)-2-(4-nitrophenyl)ethenyl]-3-nitrobenzoic acid (5a): 
1
H NMR (400 MHz, 
ACETONITRILE-d3)  ppm 6.64 (br. d, J=1.00 Hz, 1 H) 7.69 (tt, J=1.00 Hz, 4 H) 7.77 (s, 1 H) 
8.04 (d, J=1.00 Hz, 1 H) 8.14 (d, J=1.00 Hz, 1 H) 8.21 (d, J=1.00 Hz, 2 H) 
13
C NMR (101 MHz, 
ACETONITRILE-d3)  ppm 124.15 (s, 1 C) 126.56 (s, 1 C) 126.90 (s, 1 C) 127.05 (s, 1 C) 
127.33 (s, 1 C) 128.34 (s, 1 C) 128.94 (s, 1 C) 130.55 (s, 1 C) 132.43 (s, 1 C) 132.80 (s, 1 C) 
133.35 (s, 1    133. 4 (s, 1    14 .   (s, 1    14 .44 (s, 1    1  .33 (s, 1     M  135-150 C 
3.3 General Procedure for Synthesis of Nitro Styrenyl Amide Derivatives (1b-5b) 
 Into a 2-neck round bottom flask was added 6.5 mmol of appropriately substituted 3-
nitro-2-styrenyl benzoic acid along with 0.2 mL of N.N-dimethylformamide (DMF). Molecular 
sieves were added to this reaction mixture and the flask was equipped with a stir bar. The 
reaction mix was allowed to stir until a homogeneous mixture was observed and thionyl chloride 
was added (1:3 mole ratio with benzoic acid starting material) via syringe into a rubber septum. 
This mixture was then refluxed for 30minutes. To an Erlenmeyer flask was added 4 mL of 20% 
sodium hydroxide (NaOH) and it was cooled below room temperature in an ice bath. Once the 
NaOH cooled, 1 mL of N-butylamine was added. The reaction mixture was removed from reflux 
and added dropwise to the cooled amine/base solution. As the reaction mix was added, the flask 
was gently swirled. The product was extracted with ethyl ether (2x 25 mL washes) and dried 
over magnesium sulfate. The product was then concentrated with rotary evaporation and dried on 
high vacuum. The crude product was then dissolved in 10 mL of dried methanol. Distilled water 
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was added drop wise (30 mL) to form slurry that was allowed to stir for an hour before product 
was isolated by vacuum filtration. Percent yields for this reaction range from 15.9-87.7%. 
 3.3.1 2-(2-chlorostyryl)-N-butyl-3-nitrobenzamide (1b): 
1
H NMR (301 MHz, 
ACETONITRILE-d3)  ppm 0.84 (t, J=1.00 Hz, 3 H) 1.28 (br. t, J=1.00, 1.00 Hz, 2 H) 1.49 (br. 
t, J=1.00, 1.00 Hz, 2 H) 2.79 (br. d, J=1.00 Hz, 2 H) 6.96 (d, J=1.00 Hz, 2 H) 7.25 - 7.34 (m, 3 
H) 7.43 (br. t, J=1.00, 1.00 Hz, 4 H) 7.61 (br. s., 1 H) 7.75 (br. s., 1 H) 7.88 (br. s., 1 H) 
13
C 
NMR (101 MHz, ACETONITRILE-d3)  ppm -0.   (s, 1    -0.0  (s, 1    0.14 (s, 1    0.35 (s, 1 
   0.4  (s, 1    0.55 (s, 1    0.   (s, 1    0.   (s, 1    11 .34 (s, 1      M  14 -15   
 3.3.2 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b): 
1
H NMR (301 
MHz, ACETONITRILE-d3)  ppm 0.76 (d, J=7.10 Hz, 2 H) 1.27 (br. t, J=1.00, 1.00 Hz, 1 H) 
1.41 (br. d, J=1.00 Hz, 1 H) 3.26 (s, 2 H) 7.03 (br. s., 1 H) 7.40 (br. s., 1 H) 7.47 - 7.63 (m, 2 H) 
7.66 - 7.77 (m, 2 H) 7.88 (br. s., 1 H) 8.00 (br. s., 1 H) 
13
C NMR (101 MHz, ACETONITRILE-
d3)  ppm 12.92 (s, 1 C) 19.78 (s, 1 C) 31.15 (s, 1 C) 39.14 (s, 1 C) 123.07 (s, 1 C) 124.66 (s, 1 
C) 124.88 (s, 1 C) 125.79 (s, 1 C) 126.52 (s, 1 C) 126.94 (s, 1 C) 127.55 (s, 1 C) 128.44 (s, 1 C) 
128.71 (s, 1 C) 129.33 (s, 1 C) 129.88 (s, 1 C) 131.63 (s, 1    131. 1 (s, 1    13 .   (s, 1    
135.13 (s, 1    13 . 5 (s, 1    14 . 5 (s, 1    1  . 5 (s, 1      M  110-11   
 3.3.3 2-(4-chlorostyryl)-N-butyl-3-nitrobenzamide (3b): 
1
H NMR (400 MHz, 
ACETONITRILE-d3)  ppm 0.76 (d, J=1.00 Hz, 3 H) 1.23 (br. t, J=1.00, 1.00 Hz, 2 H) 1.38 (br. 
t, J=1.00, 1.00 Hz, 2 H) 3.23 (br. d, J=1.00 Hz, 2 H) 6.72 (br. d, J=1.00 Hz, 1 H) 7.28 - 7.57 (m, 
6 H) 7.69 (br. d, J=1.00 Hz, 1 H) 7.98 (br. d, J=1.00 Hz, 1 H)  
13
C NMR (101 MHz, 
ACETONITRILE-d3)  ppm 12.94 (s, 1 C) 19.80 (s, 1 C) 31.24 (s, 1 C) 38.99 (s, 1 C) 39.12 (s, 1 
C) 122.99 (s, 1 C) 124.82 (s, 1 C) 128.19 (s, 1 C) 128.36 (s, 1 C) 128.86 (s, 1 C) 130.03 (s, 1 C) 
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131.91 (s, 1 C) 132.25 (s, 1 C) 133.20 (s, 1 C) 133.57 (s, 1 C) 135.29 (s, 1 C) 13 .   (s, 1    
14 .1  (s, 1    1  .4  (s, 1      M  13 -14   
 3.3.4 2-(4-bromostyryl)-N-butyl-3-nitrobenzamide (4b): 
1
H NMR (400 MHz, 
ACETONITRILE-d3)  ppm 0.76 (d, J=1.00 Hz, 3 H) 1.25 (t, J=1.00 Hz, 2 H) 1.37 (t, J=1.00 
Hz, 2 H) 3.23 (t, J=1.00 Hz, 2 H) 6.70 (br. s., 1 H) 7.35 (s, 1 H) 7.41 (d, J=1.00 Hz, 2 H) 7.55 (t, 
J=1.00 Hz, 3 H) 7.70 (s, 1 H) 7.97 (s, 1 H) 
13
C NMR (101 MHz, ACETONITRILE-d3)  ppm 
12.94 (s, 1 C) 19.81 (s, 1 C) 31.24 (s, 1 C) 39.12 (s, 1 C) 121.77 (s, 1 C) 122.58 (s, 1 C) 123.09 
(s, 1    1 4. 3 (s, 1    1  .3  (s, 1    1  .45 (s, 1    130.03 (s, 1    130. 3 (s, 1    131.0  (s, 
1    131. 4 (s, 1    131. 3 (s, 1    133.   (s, 1    135.   (s, 1    13 . 1 (s, 1    1  .4  (s, 1 
     M  1  -1 5  
 3.3.5 2-(4-nitrostyryl)-N-butyl-3-nitrobenzamide (5b): 
1
H NMR (400 MHz, 
ACETONITRILE-d3)  ppm 0.82 (br. d, J=1.00 Hz, 3 H) 1.42 (br. t, J=1.00, 1.00 Hz, 2 H) 2.11 
(br. t, J=1.00, 1.00 Hz, 2 H) 3.20 (br. d, J=1.00 Hz, 2 H) 6.85 (br. d, J=1.00 Hz, 2 H) 7.47 - 7.79 
(m, 6 H) 8.02 (br. s., 1 H) 8.23 (br. s, 1 H) 
13
C NMR (101 MHz, ACETONITRILE-d3)  ppm 
10.76 (s, 1 C) 22.30 (s, 1 C) 41.20 (s, 1 C) 55.67 (s, 1 C) 124.10 (s, 1 C) 125.04 (s, 1 C) 127.18 
(s, 1 C) 127.40 (s, 1 C) 128.85 (s, 1 C) 131.87 (s, 1 C) 132.10 (s, 1 C) 139.83 (s, 1 C) 142.90 (s, 
1 C  1  .3  (s, 1      M  14 -15    
25 
 
 
CHAPTER 4 
Results and Discussion 
4.1 Synthesis and Characterization of Nitro-Styrenyl Benzoic Acids 
 The synthesis for compounds 1a-5a is a base catalyzed condensation reaction. The base 
used in our case is 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The base deprotonates the methyl 
group at the ortho position creating a carbanion that attacks the carbonyl on a benzaldehyde 
(Figure 18).  
O O
H3C
H
NO2
O O
CH3
CH2
NO2
+ H R
O
Base:
 
Figure 17: Synthesis of Nitro Styrenyl Benzoic Acids (Scheme A) 
A ring is then formed in an intermediate structure by the alkoxide attacking the carbonyl on the 
nitrobenzoate. A carbonyl is reformed as a methoxy group is released, Figure 19.  
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Figure 18: Synthesis of Nitro Styrenyl Benzoic Acids (Scheme B) 
The base (DBU) then opens the ring, by extracting the most acidic proton and forming the alkene 
with heat (55    is applied to the reaction. Concentrated hydrochloric acid is used in the workup 
step to protonate the product forming the carboxylic acid (Figure 20). The reaction is specific to 
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the trans-alkene formation due to minimized unfavorable steric interactions shown in the trans 
product over the cis product. This is a one pot reaction and the products can be extracted in ethyl 
acetate.  
OH3C R
H
H
Base:

OO
R
NO2
HCl
OHO
R
NO2  
Figure 19: Synthesis of Nitro Styrenyl Benzoic Acids (Scheme C) 
 4.1.1 Nitro-Styrenyl Benzoic Acid Products: Compounds 1a-5a are shown in the table 
below with a summary of percent yields for the nitrostyrenyl benzoic acids which ranged from 
35.1-90.2%. Products were all solid. All products were yellow in color with the exception of 5a, 
which was reddish-brown. 
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Table 1 
Summary of NitroStyrenyl Benzoic Acids 
 
 
 
 4.1.2 NMR Characterization of Nitro-Styrenyl Benzoic Acids: Nuclear Magnetic 
Resonance was used to characterize the structures of compounds 1a-5a. In each spectra the peaks 
in the aromatic region (6-8ppm) are of particular interest due to the general structure. Both 
proton and carbon spectra were obtained. 
Compound Structure Name % Yield 
1a 2-[(E)-2-(2-chlorophenyl) ethenyl]-3-
nitrobenzoic acid
90.2
2a 3-nitro-2-{(E)-2-[2-
(trifluoromethyl)phenyl]ethenyl) 
benzoic acid 
73.3
3a 2-[(E)-2-(4-chlorophenyl)ethenyl]-3-
nitrobenzoic acid
35.1
4a 2-[(E)-2-(4-bromophenyl) ethenyl]-3-
nitrobenzoic acid
78.1
5a 2-[(E)-2-(4-nitrophenyl) ethenyl]-3-
nitrobenzoic acid
82.3
NO2
OHO
Cl
NO2
OHO
CF3
NO2
OHO Cl
NO2
OHO Br
NO2
OHO NO2
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 4.1.2.1 Discussion of Nitro-Styrenyl Benzoic Acid Proton NMR: The proton NMR for 3-
nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a), shows the expected peaks 
for the seven protons located on the rings in the aromatic region. There is significant overlapping 
in this region.  
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 Figure 20: 
1
H NMR Spectra for 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl}benzoic 
acid (2a) 
The proton on the carbon number 10 in Figure 21, one of the double bond carbons of the styrene 
moiety, can be seen as the doublet at 6.84ppm. The proton on the other styrene carbon numbered 
9 is shown within the overlapping at 7.52ppm.The styrene proton closest to the carboxylic acid 
containing ring will be more downfield due to electronic effects. The proton of the carboxylic 
acid is not seen in the spectra due to the deuterated acetonitrile NMR solvent used which can 
exchange with the labile hydrogen of the product. 
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 Figure 21: Aromatic Region of the 1H NMR Spectra for 3-nitro-2-{(E)-2-[2-
(trifluoromethyl)phenyl]ethenyl}benzoic acid (2a) 
Table 2 
Chemical Shifts for 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a) 
No.  (ppm)  (Hz)  Height 
1  6.84  2056.7  0.0097 
2  7.52  2262.0  0.1138 
3  7.64  2297.5  0.1975 
4  7.73  2323.5  0.1441 
5  7.93  2383.8  0.0982 
6  8.03  2416.4  0.1428 
7  8.13  2445.9  0.1511 
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 4.1.2.2 Discussion of Nitro-Styrenyl Benzoic Acid Carbon NMR: The carbon NMR 
spectra for the 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a) product 
shows the sixteen carbons including that of the trifluoromethyl group. The carboxylic acid 
carbon is shown at 166.68ppm and the triflouromethyl carbon at 117.35ppm. 
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Figure 22: 
13
C NMR Spectra for 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic 
acid (2a) 
The aromatic region shown in Figure 23 shows that the carbon attached to the nitro functional 
group is observed at 150.41ppm. The alkene carbons of the styrene are observed at 125.75ppm 
and 126.74ppm. The carbons associated with the two aromatic rings are observed within the 
range of 127-136ppm. 
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Figure 23: 
13
C NMR Spectra for 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic 
acid (2a) 
Table 3 
13
C Chemical Shifts for 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a)
 
No.  (ppm)  (Hz)  Height 
1  117.35  11795.8  0.5547 
2  123.03  12367.3  0.0221 
3  125.75  12640.4  0.0286 
4  125.82  12647.3  0.0494 
5  125.88  12653.4  0.0618 
6  126.68  12733.5  0.0251 
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Table 3 
Cont. 
7  126.74  12740.4  0.1290 
8  127.74  12840.3  0.1935 
9  127.88  12854.8  0.0623 
10  128.31  12898.3  0.1843 
11  128.39  12905.9  0.1003 
12  128.71  12938.0  0.1496 
13  130.03  13070.7  0.0407 
14  131.34  13202.0  0.0328 
15  132.33  13301.9  0.0209 
16  132.44  13312.6  0.0583 
 
 4.1.3 Discussion of FT-IR of Nitro-Styrenyl Benzoic Acid: Fourier Transform Infrared 
Spectroscopy (FT-IR) can be used to confirm structures of organic compounds. This instrument 
was especially useful in this study as the conversion from a carboxylic acid to an amide was 
made. For the nitrostyrenyl benzoic acids, compounds 1a-5a, a large O-H stretch is expected due 
to the carboxylic acid. The carbonyl strectch is also a key indicator of these compounds. 
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Figure 24: FT-IR Spectra of 2-[(E)-2-(4-bromophenyl) ethenyl]-3-nitrobenzoic acid (4a) 
In the FT-IR spectra of 2-[(E)-2-(4-bromophenyl) ethenyl]-3-nitrobenzoic acid (4a), the large O-
H stretch can be seen from 3300-2400 1/cm. The carbonyl stretch is shown at 1700 1/cm. 
4.2 Synthesis and Characterization of Nitrostyrenyl Amides 
 The synthesis of the nitrostyrenyl amides can be broken down into two key parts. The 
first part is the formation of an acid chloride. The mechanism for this is shown in Figure 26. 
Thionyl chloride reacts with the carbonyl of the carboxylic acid of the nitrostyrenyl benzoic 
acids. This is followed by a [1, 2] addition of a chlorine (Figure 26) and the subsequent [1, 2] 
elimination (Figure 27). Chlorine then deprotonates the intermediate to achieve an acid chloride. 
This reaction also gives side products of SO2 (g) and HCl (g). 
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Figure 25: Formation of an Acid Chloride from a Carboxylic Acid, [1,2] addition 
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Figure 26: Formation of an Acid Chloride from a Carboxylic Acid , [1,2] elimination 
 The formation of the acid chloride is then followed by a simple SN2 substitution reaction 
in which a base (sodium hydroxide) is used to deprotonate an amine (N-butylamine) in order to 
replace the chlorine on the acid chloride and form the desired amide. 
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Figure 27: Formation of the Amide 
The base will deprotonate the amine before the attack of the carbonyl in this case due to the fact 
that sodium hydroxide is a strong base. 
 4.2.1 Use of N,N-dimethylformamide as a Catalyst: The key step of forming the acid 
chloride can also be achieved by using N,N-Dimethylformamide (DMF) as a catalyst. The use of 
DMF allows for a quick and efficient synthesis. 
H3C
N
CH3
H O
 
Figure 28: Structure of N,N-Dimethylformamide (DMF) 
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Figure 29: Formation of an Acid Chloride Using Thionyl Chloride & DMF catalyst, Scheme 1 
In the mechanism shown, DMF and thionyl chloride react first and a new C=N bond is formed. 
An unstable chloroimide intermediate containing a carbon-nitrogen double bond is formed when 
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a chlorine anion is released that can then attack the carbon of the C=N bond. Sulfer dioxide gas 
and chloride gas are released and a chloroimide intermediate forms which can react with the 
nitrostyrenyl carboxylic acid compound, Figure 30. 
S
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N
Cl
CH3
CH3
-SO2 (g)
-Cl (g)
R OH
O
Cl N
CH3
CH3
- H+
R O
O
NCl
CH3
CH3  
Figure 30: Formation of an Acid Chloride Using Thionyl Chloride & DMF catalyst ,Scheme 2 
In the final step of the mechanism (Figure 32) the acid chloride is produced and the DMF 
catalyst is regenerated. 
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Figure 31: Formation of an Acid Chloride Using Thionyl Chloride & DMF catalyst, Scheme 3 
chloroimide 
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 4.2.2 Nitro Styrenyl Amide Products: The nitrostyrenyl amide products, 1b-5b, are 
shown in the table below with a percent yield range 15.9-87.7%.  
Table 4 
Summary of Nitrostyrenyl Amide Products 
 
 4.2.3 NMR Characterization of Nitro-Styrenyl Amides: The NMR spectra for the 
amide derivatives show key differences from the nitrostyrenyl benzoic acids. The N-butyl chain 
is observed in the spectra in the region between 0.5-3.5ppm. 
Compound Structure Name % Yield 
1b 2-(2-chlorostyryl)-N-butyl-3-
nitrobenzamide 
87.7
2b 2-(2-(trifluoromethyl)styryl)-N-butyl-
3-nitrobenzamide 
15.9
3b 2-(4-chlorostyryl)-N-butyl-3-
nitrobenzamide 
57.2
4b 2-(4-bromostyryl)-N-butyl-3-
nitrobenzamide 
48.8
5b 2-(4-nitrostyryl)-N-butyl-3-
nitrobenzamide
61.7
O2N
NH
O
NO2
CH3
O2N
NH
O
Br
CH3
O2N
NH
O
Cl
CH3
O2N
NH
O
CH3
F3C
O2N
NH
O
CH3
Cl
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 4.2.3.1 Discussion of Nitro-Styrenyl Amide Proton NMR: The proton NMR spectra for 
2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) shows the four peaks for the N-
butyl chain at 0.76ppm, 1.27ppm, 1.41ppm and 3.26ppm. The proton on the carbon adjacent to 
the nitrogen shows up at 3.26ppm. The protons of the N-butyl chain are in a 2:2:2:3 ratio (-
CH2CH2CH2CH3) in terms of integration. The nine protons on the ring structures (also including 
the two styrenyl protons) are shown in the aromatic region from 7.03-8.00ppm.The N-H proton 
does not show up in the spectra due to the acetonitrile solvent used. 
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Figure 32: 
1
H NMR of 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
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Table 5 
Summary of Proton Chemical Shifts for 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide 
(2b) 
No.  (ppm)  (Hz)  Height 
1  0.74  222.5  0.0406 
2  0.76  229.6  0.0900 
3  0.79  236.7  0.0516 
4  1.27  382.8  0.0353 
5  1.41  423.6  0.0371 
6  3.26  980.2  0.0469 
7  7.03  2114.1  0.0087 
8  7.40  2225.3  0.0084 
9  7.56  2273.2  0.0216 
10  7.73  2324.7  0.0549 
11  7.88  2369.0  0.0184 
12  8.00  2405.7  0.0118 
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 4.2.3.2 Discussion of Nitro-Styrenyl Amide Carbon NMR: The carbons of the aromatic 
ring and Styrenyl carbons will be observed in the same region for the amide derivatives. 
However, the four carbons associated with the N-butyl chain will also be observed in the 
aliphatic region. 
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Figure 33: 
13
C NMR Spectra for 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
 The chemical shifts for the twenty carbons of the 2-(2-(trifluoromethyl)styryl)-N-butyl-3-
nitrobenzamide (2b) product are given in  Table 8. 
Table 6 
13
C NMR Chemical Shifts for 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
No.  (ppm)  (Hz)  Height 
1  12.92  1299.0  0.0937 
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Table 6 
Cont. 
2  19.78  1987.9  0.1068 
3  31.15  3130.8  0.0739 
4  39.14  3934.2  0.0550 
5  117.33  11794.3  0.5576 
6  124.88  12553.4  0.0655 
7  125.88  12653.4  0.0324 
8  125.94  12659.5  0.0298 
9  126.94  12760.2  0.0514 
10  127.55  12821.2  0.0949 
11  128.44  12911.3  0.0827 
12  128.71  12938.0  0.0822 
13  129.31  12998.2  0.0300 
14  129.33  13000.5  0.0325 
15  129.88  13055.5  0.0200 
16  131.91  13259.9  0.0810 
17  132.68  13337.0  0.0350 
18  132.69  13338.5  0.0381 
19  149.25  15002.5  0.0091 
20  167.25  16812.3  0.0168 
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Figure 35 shows the aliphatic region of the spectra and the four carbons of the N-butyl chain at 
12.92ppm, 19.78ppm, 31.15ppm and 39.14ppm.  
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Figure 34: 
13
C NMR Aliphatic region for 2-(2-(trifluoromethyl)styryl)-N-butyl-3-
nitrobenzamide (2b) 
The carbon spectra in Figure 36 show the aromatic region. The trifluoromethyl carbon is 
observed at 117.33ppm. The carbonyl carbon is observed at 167.26ppm and the carbon with the 
nitro functional group attached is observed at 149.25ppm. All aromatic ring carbons are observed 
in the region of 126-133ppm with those associated with the amide ring being more downfield. 
The carbons associated with the alkene are observed at 124.88ppm and 125.88ppm. 
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Figure 35: 
13
C NMR Aromatic region for 2-(2-(trifluoromethyl)styryl)-N-butyl-3-
nitrobenzamide (2b) 
 4.2.4 Discussion of FT-IR of Nitro-Styrenyl Amide: The FT-IR spectra for 2-(2-
(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) is shown below. The large O-H stretch 
seen in the spectra for compound 2a is no longer seen in the amide derivative.  
44 
 
 
 
Figure 36: FT-IR Spectra of 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
The smaller N-H stretch can be seen at 3300 1/cm. The N-H stretch also shows an overtone at 
3150 1/cm. From 3000-2900 1/cm the C-N stretch can be seen. The Carbonyl stretch for the 
amide derivative is shown at 1670 1/cm. 
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4.3 Use of HPLC to Determine Purity of Compounds 
 High performance liquid chromatography (HPLC) can be used to determine purity and 
content of organic compounds. A pure compound will show a single peak at the expected elution 
time. 
 
Figure 37:  HPLC Chromatogram for 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} 
benzoic acid (2a) 
The chromatogram for compound 2a shows an elution time of 4.5 minutes. 
 
Figure 38:HPLC Chromatogram for 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
The chromatogram for the amide derivative of compound 2a (compound 2b) shows an elution 
time of 4.9 minutes. The amide derivative should be expected to have a higher retention time due 
to the difference in mass and a stronger interaction with the absorption material. The amide 
derivative also shows a small impurity at 4.5 minutes which is most likely a small percentage of 
left over starting material. 
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4.4 Fluorine NMR Characterization of Compounds 2a and 2b 
 Fluorine NMR was also used to characterize compounds 2a and 2b due to the 
trifluoromethyl groups at the ortho position of each structure. 
NO2
O OH
CF3
 
Figure 39: Structure of 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a) 
NO2
O
H
N
CF3
 
Figure 40: 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
The fluorine NMR spectrum for compound 2a, Figure, shows a single peak for the 
trifluoromethyl group at -59.95ppm. 
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Figure 41: Fluorine NMR Spectra for 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} 
benzoic acid (2a) 
The spectrum for the fluorine NMR of compound 2b, shows two peaks at -59.70ppm and -
59.75ppm. Only one peak is expected for this structure and the observation of two peaks 
suggests that either an impurity such as the acid chloride is present or that a resonance form of 
the product is also present in the product. A resonance form would show a slight difference in 
chemical shift for the trifluoromethyl group as observed in the spectrum.  
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Figure 42: Fluorine NMR Aromatic region for 2-(2-(trifluoromethyl)styryl)-N-butyl-3-
nitrobenzamide (2b) 
4.5 Biological Analysis Using the NC-60 Cell Line Screening  
 The NCI60 anticancer drug screening program was developed by the US National Cancer 
Institute in the 1980s. The screen was developed in order to expand the scope of cancer drug 
discovery beyond leukemia models from transplantable murine neoplasms (Shoemaker, 2006). 
These previous modeled studies were not ideal for examining clinical activity and there was a 
need for a method to test solid human tumors. Researchers began with renal epithelial cells and 
found that they responded in vitro to anti-cancer drugs. Realizing that other tumor cell lines were 
needed as controls, panels of cell lines were created. These panels represent the nine major tumor 
types: leukemia, colon, lung, CNS (central nervous system), renal, melanoma, ovarian, breast 
and prostate (Shoemaker, 2006). 
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 4.5.1 Testing Results for 2-[(E)-2-(4-chlorophenyl)ethenyl]-3-nitrobenzoic acid (3a): 
The testing results for 2-[(E)-2-(4-chlorophenyl)ethenyl]-3-nitrobenzoic acid (3a) have been 
obtained from the National Institutes of Health. These results are summarized in the graph 
below, Figure 44. The diagram shows the effect of the compound on the growth rate for each cell 
line. The goal is to exhibit the lowest growth percent possible for the cancerous cells. These 
results are from a single dosage testing on the NCI60 cancer cell line. Compound 3a did not 
exhibit favorable results in the study. In each cell line tested, 3a neither slowed the growth of 
cancerous cells nor caused them to go into apoptosis. The best result came from the non-small 
cell lung cancer line HOP-92 which inhibited growth by 13.56%.   
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Figure 43: NCI60 Single Dose Test Results for Compound 3a 
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CHAPTER 5 
Future Research 
 5.1 Conclusion and Future Work 
 The amide derivatives synthesized will undergo screening with the NCI60 cell line. The 
results of these studies will be used to determine a pattern of biological activity for the 
compounds. Additional amide derivatives will be synthesized and tested in order to establish the 
most accurate pattern. It is expected that the amide derivatives will show greater activity towards 
the cell lines than the carboxylic acid compounds have shown. It is also believed that the amide 
functionality should minimize the growth rate of the cancer cells.  
 In addition to the derivatives achieved with the N-butyl amine, compounds with other 
amine groups will also be synthesized for biological testing. The goal is to gain an understanding 
of the effect nitrostyrenyl amides have on the processes of cancer cell proliferation and 
apoptosis. Once a pattern is established it can be used to create better chemopreventives. 
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Appendix A 
1
H NMR Spectra 
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Figure 1.A: 2-[(E)-2-(2-chlorophenyl) ethenyl]-3-nitrobenzoic acid (1a) 
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Figure 2.A: 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a) 
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Figure 3.A: 2-[(E)-2-(4-chlorophenyl)ethenyl]-3-nitrobenzoic acid (3a) 
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Figure 4.A: 2-[(E)-2-(4-bromophenyl) ethenyl]-3-nitrobenzoic acid (4a) 
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Figure 5.A: 2-[(E)-2-(4-nitrophenyl)ethenyl]-3-nitrobenzoic acid (5a) 
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Figure 6.A: 2-(2-chlorostyryl)-N-butyl-3-nitrobenzamide (1b) 
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Figure 7.A: 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
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Figure 8.A: 2-(4-chlorostyryl)-N-butyl-3-nitrobenzamide (3b) 
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Figure 9.A: 2-(4-bromostyryl)-N-butyl-3-nitrobenzamide (4b) 
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Figure 10.A: 2-(4-nitrostyryl)-N-butyl-3-nitrobenzamide (5b) 
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Appendix B 
13
C NMR Spectra 
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Figure 1.B: 2-[(E)-2-(2-chlorophenyl) ethenyl]-3-nitrobenzoic acid (1a) 
trifluorostyreneC13.esp
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Figure 2.B: 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a) 
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Figure 3.B: 2-[(E)-2-(4-chlorophenyl)ethenyl]-3-nitrobenzoic acid (3a) 
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Figure 4.B: 2-[(E)-2-(4-bromophenyl) ethenyl]-3-nitrobenzoic acid (4a) 
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Figure 5.B: 2-[(E)-2-(4-nitrophenyl)ethenyl]-3-nitrobenzoic acid (5a) 
trifluoroamide Carbon13.esp
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Figure 6.B: 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
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Figure 7.B: 2-(4-chlorostyryl)-N-butyl-3-nitrobenzamide (3b) 
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Figure 8.B: 2-(4-bromostyryl)-N-butyl-3-nitrobenzamide (4b) 
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Figure 9.B: 2-(4-nitrostyryl)-N-butyl-3-nitrobenzamide (5b) 
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Appendix C 
FT-IR Spectra 
 
Figure 1.C: 2-[(E)-2-(2-chlorophenyl) ethenyl]-3-nitrobenzoic acid (1a) 
 
Figure 2.C: 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a) 
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Figure 3.C: 2-[(E)-2-(4-chlorophenyl)ethenyl]-3-nitrobenzoic acid (3a) 
 
Figure 4.C: 2-[(E)-2-(4-bromophenyl) ethenyl]-3-nitrobenzoic acid (4a) 
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Figure 5.C: 2-[(E)-2-(4-nitrophenyl)ethenyl]-3-nitrobenzoic acid (5a) 
 
Figure 6.C: 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
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Figure 7.C: 2-(4-chlorostyryl)-N-butyl-3-nitrobenzamide (3b) 
 
 
Figure 8.C: 2-(4-bromostyryl)-N-butyl-3-nitrobenzamide (4b) 
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Appendix D  
HPLC Chromatograms  
 
Figure 1.D: 2-[(E)-2-(2-chlorophenyl) ethenyl]-3-nitrobenzoic acid (1a) 
 
 
Figure 2.D: 3-nitro-2-{(E)-2-[2-(trifluoromethyl)phenyl]ethenyl} benzoic acid (2a) 
 
 
Figure 3.D: 2-[(E)-2-(4-chlorophenyl)ethenyl]-3-nitrobenzoic acid (3a) 
 
 
Figure 4.D: 2-[(E)-2-(4-bromophenyl) ethenyl]-3-nitrobenzoic acid (4a) 
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Figure 5.D: 2-[(E)-2-(4-nitrophenyl)ethenyl]-3-nitrobenzoic acid (5a) 
 
 
Figure 6.D: 2-(2-chlorostyryl)-N-butyl-3-nitrobenzamide (1b) 
 
 
Figure 7.D: 2-(2-(trifluoromethyl)styryl)-N-butyl-3-nitrobenzamide (2b) 
 
 
Figure 8.D: 2-(4-chlorostyryl)-N-butyl-3-nitrobenzamide (3b) 
 
Figure 9.D: 2-(4-bromostyryl)-N-butyl-3-nitrobenzamide (4b) 
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Figure 10.D: 2-(4-nitrostyryl)-N-butyl-3-nitrobenzamide (5b) 
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